Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.
Publication
, Journal Article
Oxman, MN; Schmader, KE
Published in: Clin Infect Dis
October 2014
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
October 2014
Volume
59
Issue
7
Start / End Page
920 / 922
Location
United States
Related Subject Headings
- Neoplasms
- Microbiology
- Male
- Humans
- Herpes Zoster Vaccine
- Herpes Zoster
- Female
- Antineoplastic Agents
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Oxman, M. N., & Schmader, K. E. (2014). Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis, 59(7), 920–922. https://doi.org/10.1093/cid/ciu501
Oxman, Michael N., and Kenneth E. Schmader. “Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.” Clin Infect Dis 59, no. 7 (October 2014): 920–22. https://doi.org/10.1093/cid/ciu501.
Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014 Oct;59(7):920–2.
Oxman, Michael N., and Kenneth E. Schmader. “Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.” Clin Infect Dis, vol. 59, no. 7, Oct. 2014, pp. 920–22. Pubmed, doi:10.1093/cid/ciu501.
Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014 Oct;59(7):920–922.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
October 2014
Volume
59
Issue
7
Start / End Page
920 / 922
Location
United States
Related Subject Headings
- Neoplasms
- Microbiology
- Male
- Humans
- Herpes Zoster Vaccine
- Herpes Zoster
- Female
- Antineoplastic Agents
- 3202 Clinical sciences
- 11 Medical and Health Sciences